What question did this study set out to answer?

To assess the impact of combined anticoagulant and antiplatelet therapy on older patients with atrial fibrillation.

March 15, 2026Open Access

Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis

Key Points

To assess the impact of combined anticoagulant and antiplatelet therapy on older patients with atrial fibrillation.
Subanalysis of patients with atrial fibrillation
Comparison of OAC+APD therapy vs. OAC monotherapy
Assessment of clinical outcomes like cardiovascular death
OAC+APD therapy linked to higher cardiovascular death incidence than OAC monotherapy
No significant differences in other clinical outcomes observed
DOACs suggested as preferable to warfarin for combination therapy

Abstract

In older patients with atrial fibrillation, OAC+APD therapy was associated with higher incidence of cardiovascular death than OAC monotherapy, without significant differences in other clinical outcomes. For patients requiring combination therapy, DOACs may be preferable to warfarin.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Naruhiko Kamogawa

Kazunori Toyoda

Takenori Yamaguchi

Journals

Journal of the American Heart Association

Actions

Institutions

Kyushu University

National Cerebral and Cardiovascular Center

Cardiovascular Institute Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study